paroxetine has been researched along with cp 101,606 in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (80.00) | 29.6817 |
| 2010's | 1 (20.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Baker, B; Kolluri, S; Krams, M; Landen, JW; Menniti, FS; Preskorn, SH | 1 |
| Hashimoto, K | 1 |
| Dudka, J; Poleszak, E; Serefko, A; Stasiuk, W; Świąder, K; Szopa, A; Wlaź, P; Wyska, E | 1 |
1 trial(s) available for paroxetine and cp 101,606
| Article | Year |
|---|---|
An innovative design to establish proof of concept of the antidepressant effects of the NR2B subunit selective N-methyl-D-aspartate antagonist, CP-101,606, in patients with treatment-refractory major depressive disorder.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Double-Blind Method; Drug Resistance; Excitatory Amino Acid Antagonists; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Paroxetine; Piperidines; Psychiatric Status Rating Scales; Receptors, N-Methyl-D-Aspartate; Research Design; Selective Serotonin Reuptake Inhibitors; Severity of Illness Index; Time Factors; Treatment Failure; Young Adult | 2008 |
4 other study(ies) available for paroxetine and cp 101,606
| Article | Year |
|---|---|
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Comments on "An innovative design to establish proof of concept of the antidepressant effects of the NR2B subunit selective N-methyl-D-aspartate antagonist, CP-101,606 in patients with treatment-refractory major depressive disorder".
Topics: Antidepressive Agents; Depressive Disorder, Major; Double-Blind Method; Drug Resistance; Excitatory Amino Acid Antagonists; Humans; Infusions, Intravenous; Paroxetine; Piperidines; Psychiatric Status Rating Scales; Randomized Controlled Trials as Topic; Receptors, N-Methyl-D-Aspartate; Receptors, sigma; Research Design; Sigma-1 Receptor; Treatment Outcome | 2009 |
Influence of the selective antagonist of the NR2B subunit of the NMDA receptor, traxoprodil, on the antidepressant-like activity of desipramine, paroxetine, milnacipran, and bupropion in mice.
Topics: Analysis of Variance; Animals; Antidepressive Agents; Brain; Bupropion; Chromatography, High Pressure Liquid; Cyclopropanes; Depressive Disorder; Desipramine; Disease Models, Animal; Drug Interactions; Excitatory Amino Acid Antagonists; Injections, Intraperitoneal; Male; Mice; Milnacipran; Motor Activity; Paroxetine; Piperidines; Receptors, N-Methyl-D-Aspartate | 2017 |